A Phase I/II Trial to Evaluate the Safety and Tolerability of Berinert (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients
Phase of Trial: Phase I/II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 31 Jul 2014 Results presented at the World Transplant Congress 2014.
- 30 Jul 2014 Results were presented at the 2014 World Transplant Congress, according to a CSL Behring media release.
- 09 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History